Sign in to see private stats on your profile page — or add photo, interests, videos, mentoring, etc.

    Steven Batki, MD

    TitleProfessor
    SchoolUCSF School of Medicine
    DepartmentPsychiatry
    Address4150 Clement Street
    San Francisco CA 94121
    Phone415-221-4810x23671
    vCardDownload vCard

      Collapse Biography 
      Collapse Education and Training
      University of California, San FranciscoResidency School of Medicine

      Collapse Overview 
      Collapse Overview
      Steven L. Batki, M.D. is Professor of Psychiatry, in Residence, at the University of California, San Francisco (UCSF) School of Medicine and Chief of the Substance Abuse Programs and Director of the Addiction Psychiatry Research Program at the San Francisco VA Medical Center (SFVAMC), where he also directs the UCSF Addiction Psychiatry Fellowship Program. Dr. Batki is engaged in addiction research, training, and clinical services.

      Dr. Batki’s research and clinical interests include pharmacologic treatment for addiction to alcohol, opioids, and stimulants. His work focuses on psychiatric and medical disorders that co-occur with addiction, such as such as PTSD, traumatic brain injury (TBI), schizophrenia, and HIV/HCV. He has published extensively on clinical research in addiction and co-occurring disorders. He chaired the SAMSHA CSAT Treatment Improvement Protocol No. 37, Substance Abuse Treatment for Persons with HIV/AIDS, and Treatment Improvement Protocol No. 43, Medication-Assisted Treatment for Opioid Dependence.

      Dr. Batki's current research is supported by the Department of Defense and NIDA. His DoD projects are examining the effectiveness of pharmacotherapy for alcohol use disorders in veterans with posttraumatic stress disorder (PTSD) as well as in veterans with mild traumatic brain injury (TBI). Dr. Batki is also conducting NIDA-funded research on the pharmacotherapy of methamphetamine dependence. Recently completed NIDA and NIAAA work has included the study of hepatitis C treatment in injection drug users and the pharmacological treatment of alcohol dependence in schizophrenia.

      Collapse Interests
      psychopharmacology addictive disorders, alcohol addiction, stimulant addiction, opioid addiction, impulsivity, PTSD, traumatic brain injury

      Collapse ORNG Applications 
      Collapse Websites
      Collapse Awarded Grants
      Collapse Featured Videos

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Heinz AJ, Pennington DL, Cohen N, Schmeling B, Lasher BA, Schrodek E, Batki SL. Relations Between Cognitive Functioning and Alcohol Use, Craving, and Post-Traumatic Stress: An Examination Among Trauma-Exposed Military Veterans With Alcohol Use Disorder. Mil Med. 2016 Jul; 181(7):663-71. PMID: 27391620.
        View in: PubMed
      2. Woolley JD, Arcuni PA, Stauffer CS, Fulford D, Carson DS, Batki S, Vinogradov S. The effects of intranasal oxytocin in opioid-dependent individuals and healthy control subjects: a pilot study. Psychopharmacology (Berl). 2016 Jul; 233(13):2571-80. PMID: 27137199.
        View in: PubMed
      3. Santos GM, Coffin P, Santos D, Huffaker S, Matheson T, Euren J, DeMartini A, Rowe C, Hahn JA, Vlahov D, Vittinghoff E, Batki SL. Feasibility, Acceptability, and Tolerability of Targeted Naltrexone for Nondependent Methamphetamine-Using and Binge-Drinking Men Who Have Sex with Men. J Acquir Immune Defic Syndr. 2016 May 1; 72(1):21-30. PMID: 26674372.
        View in: PubMed
      4. Batki SL. What is the right pharmacotherapy for alcohol use disorder in patients with schizophrenia? J Clin Psychiatry. 2015 Oct; 76(10):e1336-7. PMID: 26528663.
        View in: PubMed
      5. Rubinsky AD, Chen C, Batki SL, Williams EC, Harris AH. Comparative utilization of pharmacotherapy for alcohol use disorder and other psychiatric disorders among U.S. Veterans Health Administration patients with dual diagnoses. J Psychiatr Res. 2015 Oct; 69:150-7. PMID: 26343607.
        View in: PubMed
      6. Kaplan KA, McQuaid J, Batki SL, Rosenlicht N. Behavioral treatment of insomnia in early recovery. J Addict Med. 2014 Nov-Dec; 8(6):395-8. PMID: 25369939.
        View in: PubMed
      7. Pennington DL, Abé C, Batki SL, Johannes Meyerhoff D. A preliminary examination of cortical neurotransmitter levels associated with heavy drinking in posttraumatic stress disorder. Psychiatry Res. 2014 Dec 30; 224(3):281-7. PMID: 25444536; PMCID: PMC4254450 [Available on 12/30/15].
      8. Batki SL, Pennington DL, Lasher B, Neylan TC, Metzler T, Waldrop A, Delucchi K, Herbst E. Topiramate treatment of alcohol use disorder in veterans with posttraumatic stress disorder: a randomized controlled pilot trial. Alcohol Clin Exp Res. 2014 Aug; 38(8):2169-77. PMID: 25092377; PMCID: PMC4146719.
      9. Batki SL, Pennington DL. Toward personalized medicine in the pharmacotherapy of alcohol use disorder: targeting patient genes and patient goals. Am J Psychiatry. 2014 Apr; 171(4):391-4. PMID: 24687193.
        View in: PubMed
      10. Kalapatapu RK, Ho J, Cai X, Vinogradov S, Batki SL, Mohr DC. Cognitive-behavioral therapy in depressed primary care patients with co-occurring problematic alcohol use: effect of telephone-administered vs. face-to-face treatment-a secondary analysis. J Psychoactive Drugs. 2014 Apr-Jun; 46(2):85-92. PMID: 25052784; PMCID: PMC4110640.
      11. Kalapatapu RK, Delucchi KL, Lasher BA, Vinogradov S, Batki SL. Alcohol use biomarkers predicting cognitive performance: a secondary analysis in veterans with alcohol dependence and posttraumatic stress disorder. Mil Med. 2013 Sep; 178(9):974-80. PMID: 24005546; PMCID: PMC3815580.
      12. Meszaros ZS, Abdul-Malak Y, Dimmock JA, Wang D, Ajagbe TO, Batki SL. Varenicline treatment of concurrent alcohol and nicotine dependence in schizophrenia: a randomized, placebo-controlled pilot trial. J Clin Psychopharmacol. 2013 Apr; 33(2):243-7. PMID: 23422399.
        View in: PubMed
      13. Kalapatapu RK, Lewis DF, Vinogradov S, Batki SL, Winhusen T. Relationship of age to impulsivity and decision making: a baseline secondary analysis of a behavioral treatment study in stimulant use disorders. J Addict Dis. 2013; 32(2):206-16. PMID: 23815427; PMCID: PMC3703837.
      14. Wamsley MA, Julian KA, O'Sullivan P, McCance-Katz EF, Batki SL, Satre DD, Satterfield J. Team-based learning exercise efficiently teaches brief intervention skills to medicine residents. Subst Abus. 2013; 34(4):344-9. PMID: 24159904.
        View in: PubMed
      15. Satterfield JM, O'Sullivan P, Satre DD, Tsoh JY, Batki SL, Julian K, McCance-Katz EF, Wamsley M. Using standardized patients to evaluate screening, brief intervention, and referral to treatment (SBIRT) knowledge and skill acquisition for internal medicine residents. Subst Abus. 2012; 33(3):303-7. PMID: 22738010.
        View in: PubMed
      16. Meszaros ZS, Dimmock JA, Ploutz-Snyder R, Chauhan SV, Abdul-Malak Y, Middleton FA, Batki SL. Accuracy of self-reported medical problems in patients with alcohol dependence and co-occurring schizophrenia or schizoaffective disorder. Schizophr Res. 2011 Nov; 132(2-3):190-3. PMID: 21852074; PMCID: PMC3195925.
      17. Meszaros ZS, Dimmock JA, Ploutz-Snyder RJ, Abdul-Malak Y, Leontieva L, Canfield K, Batki SL. Predictors of smoking severity in patients with schizophrenia and alcohol use disorders. Am J Addict. 2011 Sep-Oct; 20(5):462-7. PMID: 21838846; PMCID: PMC3156655.
      18. Batki SL, Canfield KM, Ploutz-Snyder R. Psychiatric and substance use disorders among methadone maintenance patients with chronic hepatitis C infection: effects on eligibility for hepatitis C treatment. Am J Addict. 2011 Jul-Aug; 20(4):312-8. PMID: 21679262.
        View in: PubMed
      19. Batki SL, Canfield KM, Smyth E, Ploutz-Snyder R, Levine RA. Hepatitis C treatment eligibility and comorbid medical illness in methadone maintenance (MMT) and non-MMT patients: a case-control study. J Addict Dis. 2010 Jul; 29(3):359-69. PMID: 20635285.
        View in: PubMed
      20. Funderburk JS, Sugarman DE, Maisto SA, Ouimette P, Schohn M, Lantinga L, Wray L, Batki S, Nelson B, Coolhart D, Strutynski K. The description and evaluation of the implementation of an integrated healthcare model. Fam Syst Health. 2010 Jun; 28(2):146-60. PMID: 20695672.
        View in: PubMed
      21. Karila L, Weinstein A, Aubin HJ, Benyamina A, Reynaud M, Batki SL. Pharmacological approaches to methamphetamine dependence: a focused review. Br J Clin Pharmacol. 2010 Jun; 69(6):578-92. PMID: 20565449; PMCID: PMC2883750.
      22. Raza S, Siddiqui UA, Megna JL, Schwartz TL, Batki SL. Pregabalin treatment of anxiety in patients with substance use disorders. Ann Pharmacother. 2010 May; 44(5):937-8. PMID: 20388860.
        View in: PubMed
      23. Canfield KM, Smyth E, Batki SL. Methadone maintenance patients' knowledge, attitudes, beliefs, and experiences concerning treatment for hepatitis C virus infection. Subst Use Misuse. 2010 Mar; 45(4):496-514. PMID: 20141461.
        View in: PubMed
      24. Batki SL, Canfield KM, Smyth E, Ploutz-Snyder R. Health-related quality of life in methadone maintenance patients with untreated hepatitis C virus infection. Drug Alcohol Depend. 2009 May 1; 101(3):176-82. PMID: 19233573.
        View in: PubMed
      25. Leontieva L, Dimmock J, Cavallerano M, DeRycke S, Meszaros Z, Carey K, Ploutz-Snyder R, Batki SL. Patient and provider attitudes towards monitored naltrexone treatment of alcohol dependence in schizophrenia. Am J Drug Alcohol Abuse. 2009; 35(5):273-8. PMID: 19591067.
        View in: PubMed
      26. Batki SL, Meszaros ZS, Strutynski K, Dimmock JA, Leontieva L, Ploutz-Snyder R, Canfield K, Drayer RA. Medical comorbidity in patients with schizophrenia and alcohol dependence. Schizophr Res. 2009 Feb; 107(2-3):139-46. PMID: 19022627; PMCID: PMC2649875.
      27. Batki SL, Leontieva L, Dimmock JA, Ploutz-Snyder R. Negative symptoms are associated with less alcohol use, craving, and "high" in alcohol dependent patients with schizophrenia. Schizophr Res. 2008 Oct; 105(1-3):201-7. PMID: 18701256; PMCID: PMC2582942.
      28. Gruber VA, Delucchi KL, Kielstein A, Batki SL. A randomized trial of 6-month methadone maintenance with standard or minimal counseling versus 21-day methadone detoxification. Drug Alcohol Depend. 2008 Apr 1; 94(1-3):199-206. PMID: 18243585; PMCID: PMC2821580.
      29. Leontieva L, Dimmock JA, Gately PW, Gallinger L, Ploutz-Snyder R, Batki SL. Voucher-based incentives for naltrexone treatment attendance in schizophrenia and alcohol use disorders. Psychiatr Serv. 2008 Mar; 59(3):310-4. PMID: 18308913.
        View in: PubMed
      30. Smelson DA, Dixon L, Craig T, Remolina S, Batki SL, Niv N, Owen R. Pharmacological treatment of schizophrenia and co-occurring substance use disorders. CNS Drugs. 2008; 22(11):903-16. PMID: 18840032.
        View in: PubMed
      31. Batki SL, Dimmock JA, Wade M, Gately PW, Cornell M, Maisto SA, Carey KB, Ploutz-Snyder R. Monitored naltrexone without counseling for alcohol abuse/dependence in schizophrenia-spectrum disorders. Am J Addict. 2007 Jul-Aug; 16(4):253-9. PMID: 17661192.
        View in: PubMed
      32. Sorensen JL, Haug NA, Delucchi KL, Gruber V, Kletter E, Batki SL, Tulsky JP, Barnett P, Hall S. Voucher reinforcement improves medication adherence in HIV-positive methadone patients: a randomized trial. Drug Alcohol Depend. 2007 Apr 17; 88(1):54-63. PMID: 17056206; PMCID: PMC1976289.
      33. Alleyne S, Alao A, Batki SL. Lamotrigine-associated rash and blood dyscrasias in a methadone-treatment patient with hepatitis C. Psychosomatics. 2006 May-Jun; 47(3):257-8. PMID: 16684944.
        View in: PubMed
      34. Manfredi L, Shupe J, Batki SL. Rural jail telepsychiatry: a pilot feasibility study. Telemed J E Health. 2005 Oct; 11(5):574-7. PMID: 16250821.
        View in: PubMed
      35. Ziedonis DM, Smelson D, Rosenthal RN, Batki SL, Green AI, Henry RJ, Montoya I, Parks J, Weiss RD. Improving the care of individuals with schizophrenia and substance use disorders: consensus recommendations. J Psychiatr Pract. 2005 Sep; 11(5):315-39. PMID: 16184072; PMCID: PMC2599914.
      36. Harris DS, Batki SL, Berger SP. Fluoxetine attenuates adrenocortical but not subjective responses to cocaine cues. Am J Drug Alcohol Abuse. 2004 Nov; 30(4):765-82. PMID: 15624548.
        View in: PubMed
      37. Batki SL, Harris DS. Quantitative drug levels in stimulant psychosis: relationship to symptom severity, catecholamines and hyperkinesia. Am J Addict. 2004 Oct-Dec; 13(5):461-70. PMID: 15764424.
        View in: PubMed
      38. Escamilla MA, Batki S, Reus VI, Spesny M, Molina J, Service S, Vinogradov S, Neylan T, Mathews C, Meza L, Gallegos A, Montero AP, Cruz ML, Neuhaus J, Roche E, Smith L, Leon P, Freimer NB. Comorbidity of bipolar disorder and substance abuse in Costa Rica: pedigree- and population-based studies. J Affect Disord. 2002 Sep; 71(1-3):71-83. PMID: 12167503.
        View in: PubMed
      39. Batki SL. Review: dopamine agonists are not effective for cocaine dependence. Evid Based Ment Health. 2002 Aug; 5(3):82-3. PMID: 12180450.
        View in: PubMed
      40. Batki SL. Review: antidepressants are not effective for cocaine dependence. Evid Based Ment Health. 2002 Aug; 5(3):82-3. PMID: 12180449.
        View in: PubMed
      41. Ophoff RA, Escamilla MA, Service SK, Spesny M, Meshi DB, Poon W, Molina J, Fournier E, Gallegos A, Mathews C, Neylan T, Batki SL, Roche E, Ramirez M, Silva S, De Mille MC, Dong P, Leon PE, Reus VI, Sandkuijl LA, Freimer NB. Genomewide linkage disequilibrium mapping of severe bipolar disorder in a population isolate. Am J Hum Genet. 2002 Sep; 71(3):565-74. PMID: 12119601; PMCID: PMC379193.
      42. Batki SL, Gruber VA, Bradley JM, Bradley M, Delucchi K. A controlled trial of methadone treatment combined with directly observed isoniazid for tuberculosis prevention in injection drug users. Drug Alcohol Depend. 2002 May 1; 66(3):283-93. PMID: 12062463.
        View in: PubMed
      43. Masson CL, Sorensen JL, Batki SL, Okin R, Delucchi KL, Perlman DC. Medical service use and financial charges among opioid users at a public hospital. Drug Alcohol Depend. 2002 Mar 1; 66(1):45-50. PMID: 11850135.
        View in: PubMed
      44. Delucchi KL, Batki SL, Moon J, Jacob P, Jones RT. Urine toxicology samples in cocaine treatment trials: how many need to be tested? J Addict Dis. 2002; 21(2):17-26. PMID: 11916369.
        View in: PubMed
      45. McInnes LA, Service SK, Reus VI, Barnes G, Charlat O, Jawahar S, Lewitzky S, Yang Q, Duong Q, Spesny M, Araya C, Araya X, Gallegos A, Meza L, Molina J, Ramirez R, Mendez R, Silva S, Fournier E, Batki SL, Mathews CA, Neylan T, Glatt CE, Escamilla MA, Luo D, Gajiwala P, Song T, Crook S, Nguyen JB, Roche E, Meyer JM, Leon P, Sandkuijl LA, Freimer NB, Chen H. Fine-scale mapping of a locus for severe bipolar mood disorder on chromosome 18p11.3 in the Costa Rican population. Proc Natl Acad Sci U S A. 2001 Sep 25; 98(20):11485-90. PMID: 11572994; PMCID: PMC58756.
      46. Escamilla MA, McInnes LA, Service SK, Spesny M, Reus VI, Molina J, Gallegos A, Fournier E, Batki S, Neylan T, Matthews C, Vinogradov S, Roche E, Tyler DJ, Shimayoshi N, Mendez R, Ramirez R, Ramirez M, Araya C, Araya X, Leon PE, Sandkuijl LA, Freimer NB. Genome screening for linkage disequilibrium in a Costa Rican sample of patients with bipolar-I disorder: a follow-up study on chromosome 18. Am J Med Genet. 2001 Mar 8; 105(2):207-13. PMID: 11304838.
        View in: PubMed
      47. Schiller MJ, Shumway M, Batki SL. Utility of routine drug screening in a psychiatric emergency setting. Psychiatr Serv. 2000 Apr; 51(4):474-8. PMID: 10737822.
        View in: PubMed
      48. Harris D, Batki SL. Stimulant psychosis: symptom profile and acute clinical course. Am J Addict. 2000; 9(1):28-37. PMID: 10914291.
        View in: PubMed
      49. Schiller MJ, Shumway M, Batki SL. Patterns of substance use among patients in an urban psychiatric emergency service. Psychiatr Serv. 2000 Jan; 51(1):113-5. PMID: 10647144.
        View in: PubMed
      50. Ferrando SJ, Batki SL. Substance abuse and HIV infection. New Dir Ment Health Serv. 2000; (87):57-67. PMID: 11031802.
        View in: PubMed
      51. Batki SL, Moon J, Delucchi K, Bradley M, Hersh D, Smolar S, Mengis M, Lefkowitz E, Sexe D, Morello L, Everhart T, Jones RT, Jacob P. Methamphetamine quantitative urine concentrations during a controlled trial of fluoxetine treatment. Preliminary analysis. Ann N Y Acad Sci. 2000; 909:260-3. PMID: 10911936.
        View in: PubMed
      52. Panganiban K, Jacob P, Everhart ET, Tisdale EC, Batki SL, Mendelson JE, Jones RT. Sulfonium salts as derivatizing agents. 3. Quantitation of the cocaine metabolite benzoylecgonine in urine using gas chromatography with ion-pair extraction/on-column alkylation. J Anal Toxicol. 1999 Nov-Dec; 23(7):581-5. PMID: 10595843.
        View in: PubMed
      53. Escamilla MA, McInnes LA, Spesny M, Reus VI, Service SK, Shimayoshi N, Tyler DJ, Silva S, Molina J, Gallegos A, Meza L, Cruz ML, Batki S, Vinogradov S, Neylan T, Nguyen JB, Fournier E, Araya C, Barondes SH, Leon P, Sandkuijl LA, Freimer NB. Assessing the feasibility of linkage disequilibrium methods for mapping complex traits: an initial screen for bipolar disorder loci on chromosome 18. Am J Hum Genet. 1999 Jun; 64(6):1670-8. PMID: 10330354; PMCID: PMC1377910.
      54. Sorensen JL, Mascovich A, Wall TL, DePhilippis D, Batki SL, Chesney M. Medication adherence strategies for drug abusers with HIV/AIDS. AIDS Care. 1998 Jun; 10(3):297-312. PMID: 9828973.
        View in: PubMed
      55. Ling W, Charuvastra C, Collins JF, Batki S, Brown LS, Kintaudi P, Wesson DR, McNicholas L, Tusel DJ, Malkerneker U, Renner JA, Santos E, Casadonte P, Fye C, Stine S, Wang RI, Segal D. Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction. 1998 Apr; 93(4):475-86. PMID: 9684386.
        View in: PubMed
      56. Mendelson J, Jones RT, Welm S, Brown J, Batki SL. Buprenorphine and naloxone interactions in methadone maintenance patients. Biol Psychiatry. 1997 Jun 1; 41(11):1095-101. PMID: 9146820.
        View in: PubMed
      57. Delucchi KL, Jones RT, Batki SL. Measurement properties of quantitative urine benzoylecgonine in clinical trials research. Addiction. 1997 Mar; 92(3):297-302. PMID: 9219391.
        View in: PubMed
      58. McInnes LA, Escamilla MA, Service SK, Reus VI, Leon P, Silva S, Rojas E, Spesny M, Baharloo S, Blankenship K, Peterson A, Tyler D, Shimayoshi N, Tobey C, Batki S, Vinogradov S, Meza L, Gallegos A, Fournier E, Smith LB, Barondes SH, Sandkuijl LA, Freimer NB. A complete genome screen for genes predisposing to severe bipolar disorder in two Costa Rican pedigrees. Proc Natl Acad Sci U S A. 1996 Nov 12; 93(23):13060-5. PMID: 8917544; PMCID: PMC24046.
      59. Ferrando SJ, Wall TL, Batki SL, Sorensen JL. Psychiatric morbidity, illicit drug use and adherence to zidovudine (AZT) among injection drug users with HIV disease. Am J Drug Alcohol Abuse. 1996 Nov; 22(4):475-87. PMID: 8911586.
        View in: PubMed
      60. Batki SL, Washburn AM, Delucchi K, Jones RT. A controlled trial of fluoxetine in crack cocaine dependence. Drug Alcohol Depend. 1996 Jun; 41(2):137-42. PMID: 8809502.
        View in: PubMed
      61. Freimer NB, Reus VI, Escamilla M, Spesny M, Smith L, Service S, Gallegos A, Meza L, Batki S, Vinogradov S, Leon P, Sandkuijl LA. An approach to investigating linkage for bipolar disorder using large Costa Rican pedigrees. Am J Med Genet. 1996 May 31; 67(3):254-63. PMID: 8725744.
        View in: PubMed
      62. Freimer NB, Reus VI, Escamilla MA, McInnes LA, Spesny M, Leon P, Service SK, Smith LB, Silva S, Rojas E, Gallegos A, Meza L, Fournier E, Baharloo S, Blankenship K, Tyler DJ, Batki S, Vinogradov S, Weissenbach J, Barondes SH, Sandkuijl LA. Genetic mapping using haplotype, association and linkage methods suggests a locus for severe bipolar disorder (BPI) at 18q22-q23. Nat Genet. 1996 Apr; 12(4):436-41. PMID: 8630501.
        View in: PubMed
      63. Herbst MD, Batki SL, Manfredi LB, Jones T. Treatment outcomes for methadone clients receiving lump-sum payments at initiation of disability benefits. Psychiatr Serv. 1996 Feb; 47(2):119-20, 142. PMID: 8825244.
        View in: PubMed
      64. Wall TL, Sorensen JL, Batki SL, Delucchi KL, London JA, Chesney MA. Adherence to zidovudine (AZT) among HIV-infected methadone patients: a pilot study of supervised therapy and dispensing compared to usual care. Drug Alcohol Depend. 1995 Mar; 37(3):261-9. PMID: 7796721.
        View in: PubMed
      65. Batki SL, Manfredi LB, Jacob P, Jones RT. Fluoxetine for cocaine dependence in methadone maintenance: quantitative plasma and urine cocaine/benzoylecgonine concentrations. J Clin Psychopharmacol. 1993 Aug; 13(4):243-50. PMID: 8376611.
        View in: PubMed
      66. Ferrando SJ, Batki SL. HIV-infected intravenous drug users in methadone maintenance treatment: clinical problems and their management. J Psychoactive Drugs. 1991 Apr-Jun; 23(2):217-24. PMID: 1662716.
        View in: PubMed
      67. Batki SL. Buspirone in drug users with AIDS or AIDS-related complex. J Clin Psychopharmacol. 1990 Jun; 10(3 Suppl):111S-115S. PMID: 2376626.
        View in: PubMed
      68. Batki SL. Drug abuse, psychiatric disorders, and AIDS. Dual and triple diagnosis. West J Med. 1990 May; 152(5):547-52. PMID: 2190423; PMCID: PMC1002409.
      69. Batki SL, Manfredi LB, Sorensen JL, Jacob P, Dumontet R, Jones RT. Fluoxetine for cocaine abuse in methadone patients: preliminary findings. NIDA Res Monogr. 1990; 105:516-7. PMID: 1876106.
        View in: PubMed
      70. Batki SL. Substance abuse and AIDS: the need for mental health services. New Dir Ment Health Serv. 1990; (48):55-67. PMID: 2077391.
        View in: PubMed
      71. Sorensen JL, Guydish J, Costantini M, Batki SL. Changes in needle sharing and syringe cleaning among San Francisco drug abusers. N Engl J Med. 1989 Mar 23; 320(12):807. PMID: 2922030.
        View in: PubMed
      72. Sorensen JL, Batki SL, Good P, Wilkinson K. Methadone maintenance program for AIDS-affected opiate addicts. J Subst Abuse Treat. 1989; 6(2):87-94. PMID: 2746716.
        View in: PubMed
      73. Batki SL, Sorensen JL, Gibson DR, Maude-Griffin P. HIV-infected i.v. drug users in methadone treatment: outcome and psychological correlates--a preliminary report. NIDA Res Monogr. 1989; 95:405-6. PMID: 2641010.
        View in: PubMed
      74. Batki SL. Treatment of intravenous drug users with AIDS: the role of methadone maintenance. J Psychoactive Drugs. 1988 Apr-Jun; 20(2):213-6. PMID: 3418453.
        View in: PubMed
      75. Batki SL, Sorensen JL, Faltz B, Madover S. Psychiatric aspects of treatment of i.v. drug abusers with AIDS. Hosp Community Psychiatry. 1988 Apr; 39(4):439-41. PMID: 3371914.
        View in: PubMed
      76. Dilley JW, Shelp EE, Batki SL. Psychiatric and ethical issues in the care of patients with AIDS. Psychosomatics. 1986 Aug; 27(8):562-6. PMID: 3749429.
        View in: PubMed
      Steven's Networks
      Related Concepts
      Derived automatically from this person's publications.
      _
      Co-Authors
      People in Profiles who have published with this person.
      _
      Related Authors
      People who share related concepts with this person.
      _
      Back to TOP